Category: Guest content

Securing the Right Space for Your Biotech Start-up

This is a guest post by Steven Lee, Senior Scientist in the Life Sciences Group at Environmental Health & Engineering (EH&E) Once you have the idea and the funding for a biotech start-up, you may think the biggest challenges are behind you. However, without proper planning and considerations, the environment you choose for your laboratory facility […]


Indian pharmaceutical patent prosecution: The changing role of Section 3(d)

This paper was originally published by Bhaven N. Sampat and Kenneth C. Shadlen in PLoS ONE 13(4): e0194714 under a Creative Commons license. Abstract India, like many developing countries, only recently…
The post Indian pharmaceutical patent prosecutio…


Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study

This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2…


Measuring the effectiveness and impact of an open innovation platform

This paper was originally published by Glenn P. Carroll, Sanjay Srivastava, Adam S. Volini, Marta M. Piñeiro-Núñez, and TatianaVetman in Drug Discovery Today Volume 22, Issue 5, May 2017, Pages 776-785 under…
The post Measuring the effectiveness and im…


Estimated costs of production and potential prices for the WHO Essential Medicines List

This article was originally published by Andrew M Hill, Melissa J Barber, and Dzintars Gotham in BMJ Global Health Jan 2018, 3 (1) e000571 under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. Abstract Introduction There are persi…


Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets

This article was originally published by Antti Jekunen in Drug Des Devel Ther. 2014; 8: 2009–2016 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract Decision-making is a core function…
The post Decision-makin…


Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics

Originally published by  J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski in Front. Oncol., 14 November 2017. Abstract The repositioning or…
The post Giving Drugs a Second…


Biotech in Countries Starting with “I” – Part 12: Israel

This is a guest post from Susan K Finston, President of Finston Consulting.  A little over five years ago I penned the first installment in this irregular series, focused on Israel’s tech transfer prowess and efforts to encourage innovative life-sciences. I tracked the Start-Up Nation’s incremental progress here.    In a nutshell, Israel leveraged excellence in basic science and […]


Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending

Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License. Abstract Policy Points: Our study indicates that there are opportunities…
The post Comparing Generic Dru…


Contribution of NIH funding to new drug approvals 2010–2016

This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D. Ledley in PNAS under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC…
The po…


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: